Article Text

Download PDFPDF

A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects
  1. Maximilian G Posch1,
  2. Michael Gramlich2,
  3. Margaret Sunde3,
  4. Katharina R Schmitt4,
  5. Stella H Y Lee2,
  6. Silke Richter1,
  7. Andrea Kersten1,
  8. Andreas Perrot1,
  9. Anna N Panek1,
  10. Iman H Al Khatib5,
  11. Georges Nemer5,
  12. André Mégarbané6,
  13. Rainer Dietz1,
  14. Brigitte Stiller7,
  15. Felix Berger4,
  16. Richard P Harvey2,8,
  17. Cemil Özcelik1
  1. 1Experimental and Clinical Research Center (ECRC), Charité - Universitätsmedizin, Berlin, Germany
  2. 2Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia
  3. 3School of Molecular and Microbial Biosciences, University of Sydney, New South Wales 2006, Australia
  4. 4Department for Congenital Heart Disease and Paediatric Cardiology, Charite - Universitätsmedizin Berlin and German Heart Institute Berlin, Germany
  5. 5Department of Biochemistry, American University of Beirut (AUB), Beirut, Lebanon
  6. 6Department of Medical Genetics, Faculty of Medicine, St. Joseph University, Beirut, Lebanon
  7. 7Department for Paediatric Cardiology, University of Freiburg, Freiburg, Germany
  8. 8Faculties of Medicine and Science, University of New South Wales, Kensington, New South Wales, Australia
  1. Correspondence to Dr Maximilian Posch, ECRC, Lindenberger Weg 80, 13125 Berlin, Germany; maximilian.posch{at}charite.de

Abstract

Background Ostium secundum atrial septal defects (ASDII) account for approximately 10% of all congenital heart defects (CHD), and mutations in cardiac transcription factors, including TBX20, were identified as an underlying cause for ASDII. However, very little is known about disease penetrance in families and functional consequences of inherited TBX20 mutations.

Methods The coding region of TBX20 was directly sequenced in 170 ASDII patients. Functional consequences of one novel mutation were investigated by surface plasmon resonance, CD spectropolarymetry, fluorescence spectrophotometry, luciferase assay and chromatin immunoprecipitation.

Results We found a novel mutation in a highly conserved residue in the T-box DNA binding domain (I121M) segregating with CHD in a three generation kindred. Four mutation carriers revealed cardiac phenotypes in terms of cribriform ASDII, large patent foramen ovale or cardiac valve defects. Interestingly, tertiary hydrophobic interactions within the mutant TBX20 T-box were significantly altered leading to a more dynamic structure of the protein. Moreover, Tbx20-I121M resulted in a significantly enhanced transcriptional activity, which was further increased in the presence of co-transcription factors GATA4/5 and NKX2-5. Occupancy of DNA binding sites on target genes was also increased.

Conclusions We suggest that TBX20-I121M adopts a more fluid tertiary structure leading to enhanced interactions with cofactors and more stable transcriptional complexes on target DNA sequences. Our data, combined with that of others, suggest that human ASDII may be related to loss-of-function as well as gain-of-function TBX20 mutations.

  • Congenital heart defect
  • atrial septal defect
  • patent foramen ovale
  • TBX20
  • cardiovascular medicine
  • clinical genetics
  • molecular genetics

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Maximilian G Posch, Michael Gramlich, and Margaret Sunde contributed equally to this work.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Charite, Berlin, Germany.

  • Provenance and peer review Not commissioned; externally peer reviewed.